Resting and active motor thresholds versus stimulus–response curves to determine transcranial magnetic stimulation intensity in quadriceps femoris

Background: Transcranial magnetic stimulation (TMS) is a widely-used investigative technique in motor cortical evaluation. Recently, there has been a surge in TMS studies evaluating lower-limb fatigue. TMS intensity of 120-130% resting motor threshold (RMT) and 120% active motor threshold (AMT) and TMS intensity determined using stimulus-response curves during muscular contraction have been used in these studies. With the expansion of fatigue research in locomotion, the quadriceps femoris is increasingly of interest. It is important to select a stimulus intensity appropriate to evaluate the variables, including voluntary activation, being measured in this functionally important muscle group. This study assessed whether selected quadriceps TMS stimulus intensity determined by frequently employed methods is similar between methods and muscles.Methods: Stimulus intensity in vastus lateralis, rectus femoris and vastus medialis muscles was determined by RMT, AMT (i.e. during brief voluntary contractions at 10% maximal voluntary force, MVC) and maximal motor-evoked potential (MEP) amplitude from stimulus-response curves during brief voluntary contractions at 10, 20 and 50% MVC at different stimulus intensities.Results: Stimulus intensity determined from a 10% MVC stimulus-response curve and at 120 and 130% RMT was higher than stimulus intensity at 120% AMT (lowest) and from a 50% MVC stimulus-response curve (p 0.05).Conclusions: Similar optimal stimulus intensity and maximal MEP amplitudes at 20 and 50% MVC and the minimal risk of residual fatigue at 20% MVC suggest that a 20% MVC stimulus-response curve is appropriate for determining TMS stimulus intensity in the quadriceps femoris. The higher selected stimulus intensities at 120-130% RMT have the potential to cause increased coactivation and discomfort and the lower stimulus intensity at 120% AMT may underestimate evoked responses. One muscle may also act as a surrogate in determining optimal quadriceps femoris stimulation intensity

La fonction neuromusculaire dans les maladies chroniques (évaluation, impact clinique et réentraînement)

La diminution de la force et l'exacerbation de la fatigue neuromusculaire sont fortement impliquées dans l'altération des capacités fonctionnelles, de la tolérance à l'effort et du pronostic de patients porteurs de pathologies chroniques variées. Ces altérations peuvent trouver leurs origines dans des atteintes primaires de la fonction neuromusculaire et/ou des atteintes secondaires causées par exemple, par une diminution de l'activité spontanée favorisée par une pathologie chronique. Ainsi, la faiblesse et la fatigabilité musculaire sont des symptômes très fréquemment rapportés dans les maladies neuromusculaires (myopathies/neuropathies d'origine génétique ou acquise), les pathologies impliquant le système cardiovasculaire (insuffisance cardiaque) et/ou respiratoire (broncho-pneumopathie chronique obstructive (BPCO)). Ces symptômes sont aussi fréquemment associés aux syndromes idiopathiques de douleurs chroniques accompagnées d'anomalies de la nociception (syndrome fibromyalgique). Le développement d'outils d'évaluation bien tolérés et fiables de la force, de l'endurance et de la fatigue neuromusculaire est d'une importance cruciale pour approfondir la compréhension des mécanismes physiopathologiques et pour disposer de critères de jugement de qualité dans le cadre d'études observationnelles et interventionnelles. Dans ce contexte, la stimulation artificielle électrique s'est révélée être un outil performant pour évaluer in situ la fonction musculaire chez l'humain au repos et au cours de l'exercice. Plus spécifiquement, la stimulation magnétique des troncs nerveux périphériques a montré des prédispositions intéressantes pour l'évaluation de la fonction des muscles locomoteurs et respiratoires dans le cadre clinique. Au cours de ce travail, nous avons développé des outils d'évaluation de la force, de l'endurance et de la fatigue neuromusculaire en utilisant la neurostimulation magnétique et des protocoles d'exercice potentiellement applicables chez le patient. Nous avons étudié leurs capacités à détecter des différences liées au sexe, l'âge et au statut d'entrainement. Dans un second temps, nous avons appliqué nos évaluations dans le cadre de maladies neuromusculaires et de syndromes douloureux chroniques. Chez le patient BPCO, nous avons étudié les phénomènes de fatigue des muscles respiratoires et locomoteurs, leur impact sur la réponse à l'effort ainsi que leurs relations entre eux et avec les symptômes perçus. Chez ces patients, nous avons recherché les effets d'un entraiment d'une prise en charge combinant un entrainement des muscles locomoteurs et un entrainement des muscles respiratoires sur ces paramètres.Strength loss and enhanced neuromuscular fatigue are major contributing factors of impaired functional capacities, exercise tolerance and prognosis in patients with various chronic diseases. These alterations can rely on primary deficiencies of neuromuscular function and/or secondary impairments caused by decreased spontaneous physical activity promoted by a chronic disease. Consequently, muscle weakness and enhanced fatigability are frequently reported symptoms in neuromuscular (inherited or noninherited myopathies/neuropathies), cardiovascular (chronic cardiac failure) and respiratory diseases (chronic obstructive pulmonary disease (COPD)) and idiopathic painful syndromes associated with alteration of nociception (fibromyalgia syndrome). The development of reliable and well-tolerated evaluations of muscle strength, endurance and fatigue is of major interest to better understand the physiopathology of the diseases and to provide relevant outcomes for observational or interventional studies. Artificially muscular electrical stimulation has been recognized as a valuable tool for noninvasive assessments of neuromuscular function at rest and during exercise in human. Recently, magnetic stimulation showed interesting skills to assess both peripheral and respiratory muscles in the clinical field. During this work, we developed tools to assess muscle strength, endurance and fatigue using magnetic neurostimulation and exercise protocols usable in patients. We studied its ability to detect differences related to sex, age and training status. Then we used these procedures in neuromuscular diseases and fibromyalgia syndrome. In COPD patients, we assessed respiratory and locomotor muscle fatigue and studied how these phenomena impact on exercise response and perceived symptoms. In these patients, we also assessed the combined effects of locomotor and respiratory muscle training on these parameters.SAVOIE-SCD - Bib.électronique (730659901) / SudocGRENOBLE1/INP-Bib.électronique (384210012) / SudocGRENOBLE2/3-Bib.électronique (384219901) / SudocSudocFranceF

Utilisation de la stimulation magnétique transcrânienne dans l'évaluation de la fonction motrice (aspects méthodologiques et application à l'exercice extrême)

La stimulation magnétique transcrânienne (TMS) est une technique d'investigation classiquement utilisée dans l'évaluation du cortex moteur. La TMS est utilisée dans l'étude de la fatigue afin de distinguer sa composante centrale. Peu d'études ont utilisé cette technique pour évaluer les effets de l'exercice locomoteur et aucune dans des conditions extrêmes. Ainsi, l'objectif de cette thèse était double: d'abord, répondre à certaines questions méthodologiques concernant l'utilisation de la TMS dans l'évaluation de la fatigue, en particulier du muscle quadriceps, et deuxièmement, étudier les effets de l'exercice en conditions extrêmes sur le développement de la fatigue centrale et supraspinal ainsi que sur l excitabilité et l'inhibition corticospinales. Dans les Etudes 1 et 2, l'effet de différentes approches d'une force cible avant l application d'une impulsion TMS ainsi que les différences entre les principales méthodes utilisées pour déterminer l'intensité optimale de TMS ont été étudiés. Dans l'Etude 3, l'effet d'une nuit de privation de sommeil sur les performances cognitives et physiques et les paramètres centraux a été étudié. L'effet d'un ultra-trail de 110 km sur la composante supraspinale de la fatigue centrale a été évalué dans l'Etude 4. Les conclusions principales de cette thèse sont, sur le plan méthodologique, i) que lors de l'évaluation par TMS pendant de brèves contractions volontaires, il est essentiel d appliquer l'impulsion de TMS après que la force produite par le sujet se soit stabilisée à la valeur cible et ii) qu'une courbe stimulus-réponse à 20% de la force maximale volontaire est appropriée pour déterminer l'intensité de TMS optimale dans les études portant sur l'exercice et la fatigue. De plus, bien que la privation de sommeil ait des impacts négatifs sur les performances cognitives et à l'exercice, elle n'a pas d'influence sur des paramètres neuromusculaires ni ne provoque une plus grande fatigue centrale. Une fatigue supraspinale se développe et l excitabilité corticospinale augmente au cours d exercices d'endurance/ultra-endurance en course à pied et ne vélo, tandis que les effets sur les mécanismes inhibiteurs corticospinaux sont équivoques et probablement dépendent des caractéristiques de l'exercice et de l'intensité de la TMSTranscranial magnetic stimulation (TMS) is a widely-used investigative technique in motor cortical evaluation. TMS is now being used in the investigation of fatigue to help partition the effects of central fatigue. Few studies have utilized this technique to evaluate the effects of locomotor exercise and none in conditions of extreme exercise. Therefore, the purpose of this thesis was twofold; first, to answer methodological questions pertaining to the use of TMS in fatigue evaluation, particularly of the quadriceps, and second, to investigate the effects of extreme exercise conditions on the development of central and supraspinal fatigue and corticospinal excitability and inhibition. In Studies 1 and 2, the effect of approaching a target force in different ways before the delivery a TMS pulse and the difference between commonly-employed methods of determining TMS intensity on the selection of optimal TMS intensity were investigated. In Study 3, the effect of one night sleep deprivation on cognitive and exercise performance and central parameters was investigated. The effect of a 110-km ultra-trail on the supraspinal component of central fatigue was evaluated in Study 4. The principal findings from this thesis are that during TMS evaluation during brief voluntary contractions, it is essential to deliver the TMS pulse once the force has stabilized at the target and that a stimulus-response curve at 20% MVC is appropriate for determining optimal TMS intensity in exercise and fatigue studies. Furthermore, while sleep deprivation negatively-impacted cognitive and exercise performance, it did not influence neuromuscular parameters nor result in greater central fatigue. Supraspinal fatigue develops and corticospinal excitability increases during endurance/ultra-endurance running and cycling, while the effects on inhibitory corticospinal mechanisms are equivocal and probably depend on exercise characteristics and TMS intensityST ETIENNE-Bib. électronique (422189901) / SudocSudocFranceF

Cerebral perturbations during exercise in hypoxia.: The brain during hypoxic exercise

International audienceReduction of aerobic exercise performance observed under hypoxic conditions is mainly attributed to altered muscle metabolism due to impaired O(2) delivery. It has been recently proposed that hypoxia-induced cerebral perturbations may also contribute to exercise performance limitation. A significant reduction in cerebral oxygenation during whole body exercise has been reported in hypoxia compared with normoxia, while changes in cerebral perfusion may depend on the brain region, the level of arterial oxygenation and hyperventilation induced alterations in arterial CO(2). With the use of transcranial magnetic stimulation, inconsistent changes in cortical excitability have been reported in hypoxia, whereas a greater impairment in maximal voluntary activation following a fatiguing exercise has been suggested when arterial O(2) content is reduced. Electromyographic recordings during exercise showed an accelerated rise in central motor drive in hypoxia, probably to compensate for greater muscle contractile fatigue. This accelerated development of muscle fatigue in moderate hypoxia may be responsible for increased inhibitory afferent signals to the central nervous system leading to impaired central drive. In severe hypoxia (arterial O(2) saturation <70-75%), cerebral hypoxia per se may become an important contributor to impaired performance and reduced motor drive during prolonged exercise. This review examines the effects of acute and chronic reduction in arterial O(2) (and CO(2)) on cerebral blood flow and cerebral oxygenation, neuronal function, and central drive to the muscles. Direct and indirect influences of arterial deoxygenation on central command are separated. Methodological concerns as well as future research avenues are also considered

Safety and efficacy of a 6-month home-based exercise program in patients with facioscapulohumeral muscular dystrophy

Background: Previous randomized controlled trials investigating exercise training programs in facioscapulohumeral muscular dystrophy (FSHD) patients are scarce and of short duration only. This study assessed the safety and efficacy of a 6-month home-based exercise training program on fitness, muscle, and motor function in FSHD patients. Methods: Sixteen FSHD patients were randomly assigned to training (TG) and control (CG) groups (both n = 8) in a home-based exercise intervention. Training consisted of cycling 3 times weekly for 35 minutes (combination of strength, high-intensity interval, and low-intensity aerobic) at home for 24 weeks. Patients in CG also performed an identical training program (CTG) after 24 weeks. The primary outcome was change in peak oxygen uptake (VO 2 peak) measured every 6 weeks. The principal secondary outcomes were maximal quadriceps strength (MVC) and local quadriceps endurance every 12 weeks. Other outcome measures included maximal aerobic power (MAP) and experienced fatigue every 6 weeks, 6-minute walking distance every 12 weeks, and muscle characteristics from vastus lateralis biopsies taken pre- and postintervention. Results: The compliance rate was 91% in TG. Significant improvements with training were observed in the VO 2 peak (+19%, P = 0.002) and MAP by week 6 and further to week 24. Muscle endurance, MVC, and 6-minute walking distance increased and experienced fatigue decreased. Muscle fiber cross-sectional area and citrate synthase activity increased by 34% (P = 0.008) and 46% (P = 0.003), respectively. Dystrophic pathophysiologic patterns were not exacerbated. Similar improvements were experienced by TG and CTG. Conclusions: A combined strength and interval cycling exercise-training program compatible with patients' daily professional and social activities leads to significant functional benefits without compromising muscle tissue

Cerebral hemodynamic and ventilatory responses to hypoxia, hypercapnia, and hypocapnia during 5 days at 4,350 m.

International audienceThis study investigated the changes in cerebral near-infrared spectroscopy (NIRS) signals, cerebrovascular and ventilatory responses to hypoxia and CO2 during altitude exposure. At sea level (SL), after 24 hours and 5 days at 4,350 m, 11 healthy subjects were exposed to normoxia, isocapnic hypoxia, hypercapnia, and hypocapnia. The following parameters were measured: prefrontal tissue oxygenation index (TOI), oxy- (HbO2), deoxy- and total hemoglobin (HbTot) concentrations with NIRS, blood velocity in the middle cerebral artery (MCAv) with transcranial Doppler and ventilation. Smaller prefrontal deoxygenation and larger ΔHbTot in response to hypoxia were observed at altitude compared with SL (day 5: ΔHbO2-0.6±1.1 versus -1.8±1.3 μmol/cmper mm Hg and ΔHbTot 1.4±1.3 versus 0.7±1.1 μmol/cm per mm Hg). The hypoxic MCAv and ventilatory responses were enhanced at altitude. Prefrontal oxygenation increased less in response to hypercapnia at altitude compared with SL (day 5: ΔTOI 0.3±0.2 versus 0.5±0.3% mm Hg). The hypercapnic MCAv and ventilatory responses were decreased and increased, respectively, at altitude. Hemodynamic responses to hypocapnia did not change at altitude. Short-term altitude exposure improves cerebral oxygenation in response to hypoxia but decreases it during hypercapnia. Although these changes may be relevant for conditions such as exercise or sleep at altitude, they were not associated with symptoms of acute mountain sickness

ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases

The objective of this document was to standardise published cardiopulmonary exercise testing (CPET) protocols for improved interpretation in clinical settings and multicentre research projects. This document: 1) summarises the protocols and procedures used in published studies focusing on incremental CPET in chronic lung conditions; 2) presents standard incremental protocols for CPET on a stationary cycle ergometer and a treadmill; and 3) provides patients’ perspectives on CPET obtained through an online survey supported by the European Lung Foundation. We systematically reviewed published studies obtained from EMBASE, Medline, Scopus, Web of Science and the Cochrane Library from inception to January 2017. Of 7914 identified studies, 595 studies with 26 523 subjects were included. The literature supports a test protocol with a resting phase lasting at least 3 min, a 3-min unloaded phase, and an 8- to 12-min incremental phase with work rate increased linearly at least every minute, followed by a recovery phase of at least 2–3 min. Patients responding to the survey (n=295) perceived CPET as highly beneficial for their diagnostic assessment and informed the Task Force consensus. Future research should focus on the individualised estimation of optimal work rate increments across different lung diseases, and the collection of robust normative data.The document facilitates standardisation of conducting, reporting and interpreting cardiopulmonary exercise tests in chronic lung diseases for comparison of reference data, multi-centre studies and assessment of interventional efficacy. http://bit.ly/31SXeB

Neuromuscular Consequences of an Extreme Mountain Ultra-Marathon

We investigated the physiological consequences of one of the most extreme exercises realized by humans in race conditions: a 166-km mountain ultra-marathon (MUM) with 9500 m of positive and negative elevation change. For this purpose, (i) the fatigue induced by the MUM and (ii) the recovery processes over two weeks were assessed. Evaluation of neuromuscular function (NMF) and blood markers of muscle damage and inflammation were performed before and immediately following (n = 22), and 2, 5, 9 and 16 days after the MUM (n = 11) in experienced ultra-marathon runners. Large maximal voluntary contraction decreases occurred after MUM (−35% [95% CI: −28 to −42%] and −39% [95% CI: −32 to −46%] for KE and PF, respectively), with alteration of maximal voluntary activation, mainly for KE (−19% [95% CI: −7 to −32%]). Significant modifications in markers of muscle damage and inflammation were observed after the MUM as suggested by the large changes in creatine kinase (from 144±94 to 13,633±12,626 UI L−1), myoglobin (from 32±22 to 1,432±1,209 µg L−1), and C-Reactive Protein (from <2.0 to 37.7±26.5 mg L−1). Moderate to large reductions in maximal compound muscle action potential amplitude, high-frequency doublet force, and low frequency fatigue (index of excitation-contraction coupling alteration) were also observed for both muscle groups. Sixteen days after MUM, NMF had returned to initial values, with most of the recovery process occurring within 9 days of the race. These findings suggest that the large alterations in NMF after an ultra-marathon race are multi-factorial, including failure of excitation-contraction coupling, which has never been described after prolonged running. It is also concluded that as early as two weeks after such an extreme running exercise, maximal force capacities have returned to baseline

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease:analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Background Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and LDL particle number (LDL-PN). The presence of atherosclerotic cardiovascular disease (ASCVD) increases the risk of future cardiovascular events. We evaluated the efficacy and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, among individuals with type 2 diabetes (T2DM), high LDL-C or non-HDL-C, and established ASCVD receiving maximally tolerated statin in ODYSSEY DM-DYSLIPIDEMIA (NCT02642159) and DM-INSULIN (NCT02585778). Methods In DM-DYSLIPIDEMIA, individuals with T2DM and mixed dyslipidemia (non-HDL-C ≥ 100 mg/dL; n = 413) were randomized to open-label alirocumab 75 mg every 2 weeks (Q2W) or usual care (UC) for 24 weeks, with UC options selected before stratified randomization. In DM-INSULIN, insulin-treated individuals with T2DM (LDL-C ≥ 70 mg/dL; n = 441) were randomized in a double-blind fashion to alirocumab 75 mg Q2W or placebo for 24 weeks. Study participants also had a glycated hemoglobin < 9% (DM-DYSLIPIDEMIA) or < 10% (DM-INSULIN). Alirocumab dose was increased to 150 mg Q2W at week 12 if week 8 LDL-C was ≥ 70 mg/dL (DM-INSULIN) or non-HDL-C was ≥ 100 mg/dL (DM-DYSLIPIDEMIA). Lipid reductions and safety were assessed in patients with ASCVD from these studies. Results This analysis included 142 DM-DYSLIPIDEMIA and 177 DM-INSULIN participants with ASCVD, including 95.1% and 86.4% with coronary heart disease, and 32.4% and 49.7% with microvascular diabetes complications, respectively. At week 24, alirocumab significantly reduced LDL-C, non-HDL-C, ApoB, and LDL-PN from baseline versus control. This translated into a greater proportion of individuals achieving non-HDL-C < 100 mg/dL (64.6% alirocumab/23.8% UC [DM-DYSLIPIDEMIA]; 65.4% alirocumab/14.9% placebo [DM-INSULIN]) and ApoB < 80 mg/dL (75.1% alirocumab/35.4% UC and 76.8% alirocumab/24.8% placebo, respectively) versus control at week 24 (all P < 0.0001). In pooling these studies, 66.4% (alirocumab) and 67.0% (control) of individuals reported treatment-emergent adverse events. The adverse event pattern was similar with alirocumab versus controls. Conclusions Among individuals with T2DM and ASCVD who had high non-HDL-C/LDL-C levels despite maximally tolerated statin, alirocumab significantly reduced atherogenic cholesterol and LDL-PN versus control. Alirocumab was generally well tolerated

Anomalies du système respiratoire de l'athlète d'endurance (troubles bronchiques, limitations ventilatoires et anomalies des échanges gazeux à l'exercice)

GRENOBLE1-BU Sciences (384212103) / SudocSudocFranceF